Abstract 3073
Background
Management of Ca treatment-related symptoms is an important safety issue. The value of nursing in symptom management is critical and becoming increasingly so as the treatment becomes more remarkably complex.
Methods
Qualitative research Descriptive case study Describe the problems of a 28year old dx with Hodgkin’s Disease.
Results
Chemotherapy Day Hospital (CDH) was the 1st contact with the oncology reality Focus: familiarization with a hostil atmosphere develop links between patient-nurses change of routines impact on ADL management of CT’s effects therapeutic regimen increase one’s resilience and hope while in treatment reduce long-term complications of the Ca tips to promote comfort: minimize suffering assisting patient navigation in the care continuum Relapse after 6 months New CT treatment (inpatient setting) Anxiety attacks due to the adaptation/awareness of his new condition Focus: management of bad news and CT’s side effects requested collaboration to the nurse of the CDH in the adaptation of strategies of adhesion to the new CT/hospitalization hospital routines adapted to his habits self care promotion psychological support articulation between services communication among nurses - promote the continuity of care New relapse Began immunotherapy: hospitalized after pulmonar toxicity In this scope he performed a bronchoscopy No curative therapy indication Due to tiredness/dyspnea a personalized respiratory rehabilitation plan was developed by a nurse: breathing optimization energy conservation techniques teaching positions of rest/relaxation In the end-of-life were adopted non-pharmacological strategies: relief of dyspnea (guidelines of the nurse of the bronchoscopy unit) positioning massage distraction techniques his mother was allowed to spend the night with him D/C was possible to fulfill one of his desires After a month he was admitted (neurological changes) and passed away.
Conclusions
During the treatment period of the disease the patient went through 3 distinctive services where it was necessary to have an individualized/specialized approach as well as an articulation/communication among the nurses in order to guarantee an effectively management of symptoms and the quality/safety of care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2171 - CCND1 Amplification Contributes to Immunosuppression in Head and Neck Squamous Cell Carcinoma and the Association with a Poor Response to Immune Checkpoint Inhibitors
Presenter: Chloe Huang
Session: Poster Display session 3
Resources:
Abstract
2624 - Efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with sensitive genes mutation
Presenter: Hui-Juan Cui
Session: Poster Display session 3
Resources:
Abstract
3494 - Neutrophil to Lymphocyte Ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N).
Presenter: Audrey Simonaggio
Session: Poster Display session 3
Resources:
Abstract
3964 - Predictive markers of checkpoint inhibitor activity in adult metastatic solid tumours
Presenter: Alexandra Pender
Session: Poster Display session 3
Resources:
Abstract
3041 - Blood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a multi-cancer Phase I IO Cohort
Presenter: Daniel Araujo
Session: Poster Display session 3
Resources:
Abstract
3910 - Analysis of Molecular Profile Complexities for Immunotherapy Decision Support
Presenter: Robert Dóczi
Session: Poster Display session 3
Resources:
Abstract
4836 - The Role of Tumor Neoantigens in the Differential Response to Immunotherapy (IO) in EGFR and BRAF Mutated Lung Cancers - Quantity or Quality?
Presenter: Katrina Case
Session: Poster Display session 3
Resources:
Abstract
1929 - Impact of previous corticosteroid (CS) exposure on efficacy of Programmed Cell Death-(Ligand) 1 blockade in patients with advanced Non-Small-Cell Lung Cancer (NSCLC): a single Center retrospective analysis
Presenter: Fabrizio Nelli
Session: Poster Display session 3
Resources:
Abstract
2601 - Comparison 18F-FDG-PET/CT criteria for prediction of therapy response and clinical outcome in patients with metastatic melanoma treated with Ipilimumab and PD-1 inhibitors
Presenter: Sabrina Vari
Session: Poster Display session 3
Resources:
Abstract
3628 - Predictive model for survival in advanced non-small-cell lung cancer (NSCLC) treated with frontline pembrolizumab
Presenter: Xabier Mielgo Rubio
Session: Poster Display session 3
Resources:
Abstract